Is the Information “Fair and Balanced” in Direct-to-Consumer Prescription Drug Websites?
- 1 November 2004
- journal article
- research article
- Published by Taylor & Francis in Journal of Health Communication
- Vol. 9 (6) , 529-540
- https://doi.org/10.1080/10810730490882667
Abstract
This study applies the Food and Drug Administration's (FDA's) “fair-balance disclosure” provision to examine the content of prescription drug websites, specifically focusing on the quantity and quality of risk information. The results show that even though most prescription drug websites provide both risk and benefit information, the two types of information are presented differently. This study suggests directions for regulators to consider in writing a more specific rule to ensure that information on prescription drug websites is balanced.Keywords
This publication has 16 references indexed in Scilit:
- A CONTENT ANALYSIS OF DIRECT-TO-CONSUMER (DTC) PRESCRIPTION DRUG WEB SITESJournal of Advertising, 2003
- The effect of link colour on information retrieval in educational intranet useComputers in Human Behavior, 2003
- Dilution and Negation of Consumer Information by Antifactual Content: Proposals for SolutionsJournal of Consumer Affairs, 2003
- Captured by the World Wide WebCommunication Research, 2002
- Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?The Lancet, 2001
- Riskier Than We Think? The Relationship Between Risk Statement Completeness and Perceptions of Direct to Consumer Advertised Prescription DrugsJournal of Health Communication, 2000
- Content Analysis of the World Wide WebSocial Science Computer Review, 2000
- The Microscope and the Moving Target: The Challenge of Applying Content Analysis to the World Wide WebJournalism & Mass Communication Quarterly, 2000
- Benefit and Risk Information in Prescription Drug AdvertisingHealth Marketing Quarterly, 2000
- Direct-to-Consumer AdvertisingJournal of Pharmaceutical Marketing & Management, 1987